In concordance with the cellular findings, the clinical data show that WISP2 expression is principally detected in preneoplastic disorders such as non-invasive ductal carcinoma in situ (DCIS) and atypical ductal hyperplasia, whereas WISP2 expression levels were either minimal or undetectable in invasive breast tumors [11], [16]. This evidence concerns the gene CCN5 and atypical ductal hyperplasia.